CD274 and esophageal cancer: The well‐established association of precursor chronic inflammatory lesions and high gene mutation rates with approximately 3000‐300 000 mutations per tumor gives the rationale for developing immunotherapy in esophageal cancer.18 Currently, pembrolizumab was recommended for the treatment of esophageal and esophagogastric junction (EGJ) adenocarcinoma with high microsatellite instability or deficient mismatch repair or PD‐L1‐positive.